Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Sep'23
Net Sales
35.37
45.83
30.66
50.69
41.26
52.13
41.73
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
35.37
45.83
30.66
50.69
41.26
52.13
41.73
Raw Material Cost
18.49
34.87
23.69
28.72
26.59
34.34
27.37
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
2.45
2.55
2.38
2.29
2.00
2.21
2.27
Selling and Distribution Expenses
27.64
33.17
29.45
27.25
24.51
26.53
30.19
Other Expenses
-0.10
0.00
0.14
0.03
0.08
-0.04
-0.10
Total Expenditure (Excl Depreciation)
47.62
70.61
56.97
58.60
53.90
62.64
58.85
Operating Profit (PBDIT) excl Other Income
-12.3
-24.8
-26.299999999999997
-7.9
-12.6
-10.5
-17.1
Other Income
1.08
1.80
1.24
0.74
0.52
0.73
3.72
Operating Profit (PBDIT)
-11.17
-26.80
-9.78
4.93
0.26
-0.01
-0.03
Interest
2.45
2.55
2.38
2.29
2.00
2.21
2.27
Exceptional Items
0.12
-10.12
0.07
0.02
-0.06
-40.00
-0.96
Gross Profit (PBDT)
16.88
10.96
6.97
21.97
14.67
17.79
14.35
Depreciation
0.00
15.34
15.34
12.39
12.39
13.35
13.35
Profit Before Tax
-13.50
-54.81
-27.44
-9.73
-14.19
-55.56
-16.60
Tax
0.00
-0.14
-0.06
0.30
0.00
-1.02
0.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-10.04
-40.47
-20.89
-8.20
-8.74
-49.12
-10.41
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-10.04
-40.47
-20.89
-8.20
-8.74
-49.12
-10.41
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-3.46
-14.20
-6.49
-1.83
-5.45
-5.42
-6.19
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-13.50
-54.67
-27.38
-10.03
-14.19
-54.54
-16.60
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
383.37
393.41
433.88
454.77
462.97
471.49
525.28
Earnings per share (EPS)
-0.02
-0.1
-0.05
-0.02
-0.02
-0.12
-0.03
Diluted Earnings per share
-0.02
-0.1
-0.05
-0.02
-0.02
-0.12
-0.03
Operating Profit Margin (Excl OI)
-34.64%
-95.88%
-85.99%
-16.18%
-30.64%
-27.03%
-40.98%
Gross Profit Margin
-38.17%
-86.12%
-39.47%
5.24%
-4.37%
-80.97%
-7.8%
PAT Margin
-28.39%
-88.3%
-68.14%
-16.18%
-21.19%
-94.23%
-24.95%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
Net Sales
QoQ Growth in quarter ended Mar 2025 is -22.71% vs 49.19% in Dec 2024
Consolidate Net Profit
QoQ Growth in quarter ended Mar 2025 is 75.32% vs -99.64% in Dec 2024
Operating Profit (PBDIT) excl Other Income
QoQ Growth in quarter ended Mar 2025 is 56.99% vs -160.00% in Dec 2024
Interest
QoQ Growth in quarter ended Mar 2025 is -7.69% vs 8.33% in Dec 2024
Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Mar 2025 has improved from Dec 2024
Compare Quarterly Results Of Hainan Shuangcheng Pharmaceuticals Co., Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(CNY)
Change(%)
Net Sales
35.37
0
35.37
Other Operating Income
0.00
0.00
0.00
Total Operating income
35.37
0
35.37
Raw Material Cost
18.49
0
18.49
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
2.45
0
2.45
Selling and Distribution Expenses
27.64
0
27.64
Other Expenses
-0.10
0.00
-0.10
Total Expenditure (Excl Depreciation)
47.62
0
47.62
Operating Profit (PBDIT) excl Other Income
-12.25
0.00
-12.25
Other Income
1.08
0
1.08
Operating Profit (PBDIT)
-11.17
0
-11.17
Interest
2.45
0
2.45
Exceptional Items
0.12
0
0.12
Gross Profit (PBDT)
16.88
0
16.88
Depreciation
0.00
0
0.00
Profit Before Tax
-13.50
0
-13.50
Tax
0.00
0
0.00
Provisions and contingencies
0
0
0.00
Profit After Tax
-10.04
0
-10.04
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-10.04
0
-10.04
Share in Profit of Associates
0
0
0.00
Minority Interest
-3.46
0
-3.46
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-13.50
0
-13.50
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
383.37
0
383.37
Earnings per share (EPS)
-0.02
0
-0.02
Diluted Earnings per share
-0.02
0
-0.02
Operating Profit Margin (Excl OI)
-34.64%
0%
0.00
-34.64%
Gross Profit Margin
-38.17%
0%
0.00
-38.17%
PAT Margin
-28.39%
0%
0.00
-28.39%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 3.54 Million
in Mar 2025Figures in Million
QoQ Growth in quarter ended Mar 2025 is -22.71% vs 49.19% in Dec 2024
YoY Growth in quarter ended Mar 2025 is -14.29% vs -48.12% in Mar 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit -1.35 Million
in Mar 2025Figures in Million
QoQ Growth in quarter ended Mar 2025 is 75.32% vs -99.64% in Dec 2024
YoY Growth in quarter ended Mar 2025 is 4.93% vs -14,300.00% in Mar 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -1.23 Million
in Mar 2025Figures in Million
QoQ Growth in quarter ended Mar 2025 is 56.99% vs -160.00% in Dec 2024
YoY Growth in quarter ended Mar 2025 is -4,000.00% vs -102.31% in Mar 2024
Quarterly - Interest
Interest 0.24 Million
in Mar 2025Figures in Million
QoQ Growth in quarter ended Mar 2025 is -7.69% vs 8.33% in Dec 2024
YoY Growth in quarter ended Mar 2025 is 20.00% vs -20.00% in Mar 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -34.64%
in Mar 2025Figures in %
QoQ Growth in quarter ended Mar 2025 has improved from Dec 2024
YoY Growth in quarter ended Mar 2025 has fallen from Mar 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
